Compounders Research Compare

CeriBell, Inc.(CBLL)

Medical - Devices · Sunnyvale, CA

$24.86+1.17 (+4.94%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About CeriBell, Inc.

CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.

Sunnyvale, CA

327 employees

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Xingjuan Chao

View full financials

CeriBell (CBLL) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T12:05:58.963Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:05:58.963Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 943,255,522
Total debt · period ending 2026-06-30: 21,909,000
Cash · period ending 2026-06-30: 32,663,000
TTM operating EBITDA · period ending 2026-06-30: -68,848,000

FMP input reference: cf0630fc9642b75147419b140bafddb7ccff0a2362c2d95f2dd7172ee2000ae5

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CBLL EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

CBLL Competitors' EV/EBITDA Ratio

CeriBell, Inc.

Current

Market Cap

$943.26M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Arbutus Biopharma Corp

Market Cap

$922.50M

EV/EBITDA Ratio

6.16x

TTM Avg

5.93x

3Y Avg

5.93x

5Y Avg

5.93x

Bioventus Inc.

Market Cap

$915.95M

EV/EBITDA Ratio

10.74x

TTM Avg

9.34x

3Y Avg

18.56x

5Y Avg

25.76x

Corvus Pharmaceuticals, Inc.

Market Cap

$903.13M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cullinan Therapeutics, Inc.

Market Cap

$985.79M

EV/EBITDA Ratio

N/A

TTM Avg

2.11x

3Y Avg

2.11x

5Y Avg

2.11x

Aktis Oncology, Inc.

Market Cap

$989.05M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Monte Rosa Therapeutics, Inc.

Market Cap

$867.60M

EV/EBITDA Ratio

N/A

TTM Avg

45.75x

3Y Avg

45.75x

5Y Avg

45.75x

Apnimed, Inc.

Market Cap

$866.15M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Beta Bionics, Inc.

Market Cap

$852.55M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alumis Inc.

Market Cap

$844.28M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
CeriBell, Inc. (CBLL)	$943.26M	N/A	N/A	N/A	N/A
Arbutus Biopharma Corp (ABUS)vs ›	$922.50M	6.16x	5.93x	5.93x	5.93x
Bioventus Inc. (BVS)vs ›	$915.95M	10.74x	9.34x	18.56x	25.76x
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$903.13M	N/A	N/A	N/A	N/A
Cullinan Therapeutics, Inc. (CGEM)vs ›	$985.79M	N/A	2.11x	2.11x	2.11x
Aktis Oncology, Inc. (AKTS)vs ›	$989.05M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$867.60M	N/A	45.75x	45.75x	45.75x
Apnimed, Inc. (APMD)vs ›	$866.15M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$852.55M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$844.28M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics